FDA deals ISTA a blow

Article

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

T-Pred is a topical steroid developed for the treatment of inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infections or a risk of bacterial infection exists.

A multicentre, randomized, double-blind study was conducted to determine bioequivalence of prednisolone concentrations between T-Pred and PredForte (prednisolone acetate 1.0%). ISTA believes that the study achieved or exceeded the goal, both in the intent-to-treat and the per-protocol patient populations. Furthermore, the company also believes that the study shows T-Pred to have antimicrobial activity equivalent to other combination products approved for this indication.

However, FDA assessment of the clinical data did not show sufficient equivalence between the prednisolone component in T-Pred and PredForte. ISTA disagrees with the findings and plans to request a meeting with the FDA as soon as possible to discuss the matter.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.